Evidence map›Paper›PMID 30368243›Full record

ArticleCritical care (London, England)2018

Angiotensin converting enzyme defects in shock: implications for future therapy.

Lakhmir S Chawla, Steve Chen, Rinaldo Bellomo, George F Tidmarsh

Abstract read
In one paragraph

Article in Critical care (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Redefining the modern paradigm of vasopressor therapy for vasodilatory shock.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2025
    Review
  3. Vasoactive Agents in Burn Patients: Perspectives on Angiotensin-II.Journal of burn care & research : official publication of the American Burn Association · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Angiotensin 1-7 in an experimental septic shock model.Critical care (London, England) · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020
    Review
  19. Article
  20. COVID-19 and the RAAS-a potential role for angiotensin II?Critical care (London, England) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lakhmir S ChawlaVeterans Affairs Medical Center, San Diego, CA, USA. minkchawla@gmail.com.
Steve ChenLa Jolla Pharmaceutical Company, 4550 Towne Centre Court, San Diego, CA, 92121, USA.
Rinaldo BellomoSchool of Medicine, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
George F TidmarshLa Jolla Pharmaceutical Company, 4550 Towne Centre Court, San Diego, CA, 92121, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin-Converting Enzyme 2Endothelial CellsHumansPeptidyl-Dipeptidase AShockACE2 protein, humanAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AACE defectAngiotensin insufficiencyBradykininSepsisVasodilatoryVasodilatory shock

Identifiers

PMID30368243
PMCPMC6204272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.